Bioject Advances in Vaccine Delivery with Biojector® 2000
Share:
Bioject Advances in Vaccine Delivery With Biojector® 2000
PORTLAND, Ore., Oct. 9 -- Studies presented at the Modern Vaccine Adjuvants et Delivery Systems Conference and at the AIDS Vaccine Conference 2006 show improved immunogenicity of vaccines when used with the Biojector® 2000 ("B2000") in cancer and AIDS vaccines.
In a study presented at the Modern Vaccine Adjuvants et Delivery Systems Conference held September 2006 at the Royal Society of Medicine in London, the Biojector® 2000 showed improved immunogenicity for a cancer vaccine being developed at Memorial Sloan-Kettering Cancer Center. Dr. Miguel Perales from Memorial Sloan-Kettering presented data showing improved immunogenicity when using the B2000 with a cancer vaccine for melanoma. The presentation, titled "DNA immunization against tumor antigens using the B2000, a needle free injection device, in pre-clinical mouse model," showed how the B2000 improved expression, thus making the vaccine more effective. "Injection of GM-CSF DNA with the B2000 induces measurable levels of GM-CSF protein in the skin, which are higher than those after injection with a needle and syringe," stated Dr. Perales. "Using the B2000 to administer melanoma DNA vaccines in mouse models, we were able to show tumor-specific immune responses as well as tumor protection. In addition to our positive results in clinical studies of companion animals, these results support the use of needle-free injection devices, such as the B2000, for DNA immunization in human clinical trials," said Dr. Perales. The B2000 is currently being used in human clinical trials for the melanoma vaccines as well as other vaccines being developed by Memorial Sloan-Kettering.
In another study presented by the Karolinska Institute of Sweden at the AIDS Vaccine 2006 International Conference held in Amsterdam in August 2006, the use of the B2000 showed promise in an initial HIV vaccine clinical study. The study included intramuscular and intradermal injections in 40 patients. "Initial study results look promising and we are pleased with the B2000 as a delivery method for our vaccine," commented Dr. Eric Sandstrom of the Karolinska Institute.
"We are pleased with the usage of our device and technology for the development of cancer and AIDS vaccines, as well as other vaccines being used throughout the world," said Jim O'Shea, Chairman, President and CEO of Bioject. "If we can improve the efficacy of these vaccines and provide an alternative delivery system to a needle and syringe, we will improve health care for everyone. We look forward to more exciting results as these vaccines move forward into further clinical trials."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information about Bioject, visit www.bioject.com .
FCMN Contact: SFendall@bioject.com
Source: Bioject Medical Technologies Inc.
CONTACT:
Jim O'Shea,
Chief Executive Officer,
+1-503-692-8001 ext. 4161
Web site: www.bioject.com/
